Diligence memo · auto-generated · as of July 2, 2026

Cynvec LLC

Cynvec LLC looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Cynvec LLC operates in Biotechnology, based in NEW YORK.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Cynvec LLC has raised $17M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $15M on 2017-07-01.

Most recent recorded round closed around 2017-07-01.

Valuation (modeled)modeled

Provath models Cynvec LLC at approximately $542M (range $16M–$2.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 2.57× the median modeled value of Series A Biotechnology companies in 2016–2018 (157 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 33 months.

Last raise 9.0 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 7.9× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 66% of Biotechnology peers (4293 compared).

Modeled value ranks above 84% of those peers.

Closest niche peers: Bio-Dent, LTD. LLC, Anthera Pharmaceuticals Inc, Biothera Holding Corp., Limelight Bio, Inc., Overture Life, Inc..

Peoplefiled

9 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.